10x Genomics, Inc. - $TXG STOCK NEWS

Curio Bioscience reported a favorable decision from the European Unified Patent Court (UPC) regarding a patent infringement claim by 10x Genomics. The court found that Curio Seeker does not infringe on the main claim asserted by 10x Genomics and ordered Curio Bioscience not to offer any violating products in certain countries. Curio Bioscience expects no impact on its commercial business due to this ruling.

10x Genomics, Inc. reported $141.0 million in revenue for the first quarter of 2024, a 5% increase from the same period in 2023. The company introduced four major new products, including Visium HD Spatial Gene Expression and two new Chromium products powered by GEM-X. Despite revenue growth, gross margin decreased to 66% due to product mix changes. Operating expenses rose by 3% to $154.4 million, driven by higher legal expenses and facility costs. The company saw an operating loss of $61.5 million and a net loss of $59.9 million for the quarter. 10x Genomics is maintaining its full-year 2024 revenue guidance of $670 million to $690 million, anticipating 8% to 12% growth over 2023.

10x Genomics, Inc. (TXG) will release its financial results for Q1 2024 on April 30, 2024. A conference call and webcast will follow to discuss results, business updates, and future prospects.

10x Genomics, Inc. (TXG) launches Visium HD Spatial Gene Expression product, enabling whole transcriptome spatial discovery at single cell–scale resolution. The product offers comprehensive characterization of FFPE tissue samples, combining transcriptome spatial discovery with histological insights. Visium HD provides best-in-class sequencing-based spatial transcriptomics data, FFPE compatibility, enhanced histology, and easy-to-use analysis and visualization tools.

10x Genomics, Inc. announces the commercial availability of the Xenium Cell Segmentation Kit and the launch of the Xenium Immuno-Oncology Panel. The company aims to enhance single cell spatial analysis with advanced AI algorithms and diverse stains, catering to researchers' needs for accurate cell segmentation and in-depth tumor microenvironment analysis.

10x Genomics, Inc. introduces GEM-X technology architecture, enhancing single cell analysis with improved sensitivity, scalability, cost-efficiency, and data quality. The new products, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3, offer superior performance and workflow advantages.

10x Genomics, Inc. (TXG) will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference. The event will be live-streamed on their website, with a replay option available for 45 days.

10x Genomics (TXG) reports Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over 2022. The company launched new products, increased instruments sold, and provided a positive outlook for 2024.

10x Genomics, Inc. (Nasdaq: TXG) has announced the launch of GEM-X, the next generation of the company's leading single cell technology, offering higher performance at larger scale and lower cost. The company is now accepting preorders for the first two product launches powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3'v4 and Chromium Single Cell Immune Profiling 5'v3, with expected shipping in Q1. GEM-X offers substantial performance advantages, including increased sensitivity, scalability, cost-effectiveness, enhanced data quality, maximum sample recovery, and improved assay robustness, setting a new standard for single cell analysis.